Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Rescue Surgery in Elderly Hemifacial Spasm Patients Refractory to Botulinum Toxin
Movement Disorders
P10 - Poster Session 10 (11:45 AM-12:45 PM)
3-015
Botulinum toxin is an effective treatment for hemifacial spasm (HFS) in elderly patients. However, some patients do not tolerate the side effects and frequency of botulinum toxin treatments. 

The purpose of this study was to evaluate a cohort of elderly patients referred by neurologists for surgical decompression of the facial nerve following botulinum toxin treatment.

In a prospective cohort study, we compared clinical outcomes and complications after surgical decompression in elderly patients that had received ≤8 and >8 botulinum toxin treatments for HFS prior to surgery.  The primary outcome was spasm-freedom. We performed logistic regression analyses to examine the relationship between age, sex, side, pre-operative symptom duration, number of pre-operative botulinum toxin treatments, and spasm-freedom at last follow-up.

Of 76 elderly patients with HFS treated with botulinum toxin, 84.2% were spasm-free at last follow-up (median 44.5 months) and 15.8% continued to have some spasms. Age (p=0.38, CI [0.38, 1.07], OR = 0.94), sex (p=0.59, CI [0.17, 2.89], OR = 0.68), side (p=0.15, CI [0.06, 1.54], OR = 0.31), pre-operative symptom duration (p=0.7, CI [0.5, 1.6], OR = 0.89), and number of pre-operative botulinum toxin treatments (p=0.3, CI [0.149, 1.81], OR = 0.52) were not predictors of spasm-freedom after surgical decompression.

Botulinum toxin is a highly safe and effective treatment for HFS. Despite this, a proportion of patients do not tolerate chronic treatment and the side effects of botulinum toxin treatment. This study provides evidence that elderly patients can undergo botulinum toxin treatment for HFS as long as desired without compromising their likelihood of achieving spasm-freedom if surgical decompression is performed in the future. Therefore, surgical decompression of the facial nerve serves as an effective rescue therapy for elderly patients with HFS refractory to botulinum toxin.

Authors/Disclosures
Margaret Tugend
PRESENTER
Ms. Tugend has nothing to disclose.
Christina M. Ulane, MD, PhD Dr. Ulane has nothing to disclose.
Kevin Patel No disclosure on file
Raymond Sekula No disclosure on file